Novel Administration Routes for Allergen-Specific Immunotherapy: A Review of Intralymphatic and Epicutaneous Allergen-Specific Immunotherapy

Immunology and Allergy Clinics of North America

Volumn 31, Issue 2, 2011, Pages 391-406

  von Moos, Seraina ^a   Kündig, Thomas M ^b   Senti, Gabriela ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Epicutaneous allergen specific immunotherapy; Epicutaneous vaccination; Intralymphatic allergen specific immunotherapy; Intralymphatic vaccination; Vaccination route

Indexed keywords

ANTIALLERGIC AGENT; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 6;

ALLERGIC DISEASE; ANTIBODY DETECTION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DESENSITIZATION; DRUG DELIVERY SYSTEM; DRUG SAFETY; EPICUTANEOUS ALLERGEN SPECIFIC IMMUNOTHERAPY; HUMAN; IMMUNOGENICITY; IMMUNOREACTIVITY; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; INSECT ALLERGY; INTRALYMPHATIC ALLERGEN SPECIFIC IMMUNOTHERAPY; LANGERHANS CELL; NONHUMAN; PLASMID; POLLEN ALLERGY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SKIN STRUCTURE; SOCIAL STATUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH2 CELL; VACCINATION;

ALLERGENS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; DRUG ADMINISTRATION ROUTES; HUMANS; INJECTIONS, INTRALYMPHATIC; SKIN;

EID: 79955404230     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2011.02.012     Document Type: Review

References (93)

1. Bostock J. Of the catarrhus astivus or summer catarrh. Med Chir Trans 1828, 14:437-446.
2. Holgate S.T. The epidemic of allergy and asthma. Nature 1999, 402(Suppl 6760):B2-B4.
3. Noon L. Prophylactic inoculation against hay fever. Lancet 1911, 177(4580):1572-1573.
4. Stanworth D.R. The discovery of IgE. Allergy 1993, 48(2):67-71.
5. Holgate S.T., Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol 2008, 8(3):218-230.
6. Larche M., Akdis C.A., Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006, 6(10):761-771.
7. Frew A.J. Allergen immunotherapy. J Allergy Clin Immunol 2010, 125(2 Suppl 2):S306-S313.
8. Akdis M., Akdis C.A. Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov 2009, 8(8):645-660.
9. Cox L., Calderon M.A. Subcutaneous specific immunotherapy for seasonal allergic rhinitis: a review of treatment practices in the US and Europe. Curr Med Res Opin 2010, 26(12):2723-2733.
10. Calderon M.A., Alves B., Jacobson M., et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007, 1. CD001936.
11. Senna G., Ridolo E., Calderon M., et al. Evidence of adherence to allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2009, 9(6):544-548.
12. Mitragotri S. Immunization without needles. Nat Rev Immunol 2005, 5(12):905-916.
13. Senti G., Freiburghaus A.U., Kundig T.M. Epicutaneous/transcutaneous allergen-specific immunotherapy: rationale and clinical trials. Curr Opin Allergy Clin Immunol 2010, 10(6):582-586.
14. Senti G., Johansen P., Kundig T.M. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol 2009, 9(6):537-543.
15. Cox L.S., Larenas Linnemann D., Nolte H., et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006, 117(5):1021-1035.
16. Zinkernagel R.M., Ehl S., Aichele P., et al. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997, 156:199-209.
17. Zinkernagel R.M. Localization dose and time of antigens determine immune reactivity. Semin Immunol 2000, 12(3):163-171. [discussion: 257-344].
18. Junt T., Scandella E., Ludewig B. Form follows function: lymphoid tissue microarchitecture in antimicrobial immune defence. Nat Rev Immunol 2008, 8(10):764-775.
19. Karrer U., Althage A., Odermatt B., et al. On the key role of secondary lymphoid organs in antiviral immune responses studied in alymphoplastic (aly/aly) and spleenless (Hox11(-)/-) mutant mice. J Exp Med 1997, 185(12):2157-2170.
20. Barker C.F., Billingham R.E. The role of afferent lymphatics in the rejection of skin homografts. J Exp Med 1968, 128(1):197-221.
21. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10(11):787-796.
22. Randolph G.J., Angeli V., Swartz M.A. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 2005, 5(8):617-628.
23. Matzinger P. Friendly and dangerous signals: is the tissue in control?. Nat Immunol 2007, 8(1):11-13.
24. Iwasaki A., Kelsall B.L. Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J Exp Med 1999, 190(2):229-239.
25. Everson M.P., Lemak D.G., McDuffie D.S., et al. Dendritic cells from Peyer's patch and spleen induce different T helper cell responses. J Interferon Cytokine Res 1998, 18(2):103-115.
26. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296(5566):301-305.
27. Martinez-Gomez J.M., Johansen P., Erdmann I., et al. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol 2009, 150(1):59-65.
28. Junt T., Tumanov A.V., Harris N., et al. Expression of lymphotoxin beta governs immunity at two distinct levels. Eur J Immunol 2006, 36(8):2061-2075.
29. Senti G., Prinz Vavricka B.M., Erdmann I., et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 2008, 105(46):17908-17912.
30. Juillard G.J., Boyer P.J. Intralymphatic immunization: current status. Eur J Cancer 1977, 13(4-5):439-440.
31. Kundig T.M., Bachmann M.F., DiPaolo C., et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 1995, 268(5215):1343-1347.
32. Ochsenbein A.F., Sierro S., Odermatt B., et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001, 411(6841):1058-1064.
33. Smith K.A., Tam V.L., Wong R.M., et al. Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides. Vaccine 2009, 27(19):2603-2615.
34. Weber J., Boswell W., Smith J., et al. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother 2008, 31(2):215-223.
35. Kreiter S., Selmi A., Diken M., et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 2010, 70(22):9031-9040.
36. Lehner T., Wang Y.F., Cranage M., et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 1996, 2(7):767-775.
37. Finerty S., Stokes C.R., Gruffydd-Jones T.J., et al. Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus. Vaccine 2001, 20(1/2):49-58.
38. Crameri R., Fluckiger S., Daigle I., et al. Design, engineering and in vitro evaluation of MHC class-II targeting allergy vaccines. Allergy 2007, 62(2):197-206.
39. Rhyner C., Kundig T., Akdis C.A., et al. Targeting the MHC II presentation pathway in allergy vaccine development. Biochem Soc Trans 2007, 35(Pt 4):833-834.
40. Martinez-Gomez J.M., Johansen P., Rose H., et al. Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy. Allergy 2009, 64(1):172-178.
41. Kupper T.S., Fuhlbrigge R.C. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004, 4(3):211-222.
42. Nestle F.O., Di Meglio P., Qin J.Z., et al. Skin immune sentinels in health and disease. Nat Rev Immunol 2009, 9(10):679-691.
43. Bal S.M., Ding Z., van Riet E., et al. Advances in transcutaneous vaccine delivery: Do all ways lead to Rome?. J Control Release 2010, 148(3):266-282.
44. Bos J.D., Meinardi M.M. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000, 9(3):165-169.
45. Babiuk S., Baca-Estrada M., Babiuk L.A., et al. Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J Control Release 2000, 66(2/3):199-214.
46. Merad M., Ginhoux F., Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol 2008, 8(12):935-947.
47. Streilein J.W. Skin-associated lymphoid tissues (SALT): origins and functions. J Invest Dermatol 1983, 80(Suppl):12s-16s.
48. Kapsenberg M.L. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 2003, 3(12):984-993.
49. Ueno H., Schmitt N., Klechevsky E., et al. Harnessing human dendritic cell subsets for medicine. Immunol Rev 2010, 234(1):199-212.
50. Klechevsky E., Morita R., Liu M., et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008, 29(3):497-510.
51. Kissenpfennig A., Henri S., Dubois B., et al. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 2005, 22(5):643-654.
52. Swamy M., Jamora C., Havran W., et al. Epithelial decision makers: in search of the 'epimmunome'. Nat Immunol 2010, 11(8):656-665.
53. Senti G., Graf N., Haug S., et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol 2009, 124(5):997-1002.
54. Frerichs D.M., Ellingsworth L.R., Frech S.A., et al. Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch. Vaccine 2008, 26(22):2782-2787.
55. Frech S.A., Dupont H.L., Bourgeois A.L., et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008, 371(9629):2019-2025.
56. Sullivan S.P., Koutsonanos D.G., Del Pilar Martin M., et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010, 16(8):915-920.
57. Wood L.C., Jackson S.M., Elias P.M., et al. Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. J Clin Invest 1992, 90(2):482-487.
58. Tan G., Xu P., Lawson L.B., et al. Hydration effects on skin microstructure as probed by high-resolution cryo-scanning electron microscopy and mechanistic implications to enhanced transcutaneous delivery of biomacromolecules. J Pharm Sci 2010, 99(2):730-740.
59. Mondoulet L., Dioszeghy V., Ligouis M., et al. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy 2010, 40(4):659-667.
60. Dupont C., Kalach N., Soulaines P., et al. Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol 2010, 125(5):1165-1167.
61. Eyler J.M. Smallpox in history: the birth, death, and impact of a dread disease. J Lab Clin Med 2003, 142(4):216-220.
62. Jodar L., Duclos P., Milstien J.B., et al. Ensuring vaccine safety in immunization programmes-a WHO perspective. Vaccine 2001, 19(13-14):1594-1605.
63. Glenn G.M., Taylor D.N., Li X., et al. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 2000, 6(12):1403-1406.
64. Frech S.A., Kenney R.T., Spyr C.A., et al. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 2005, 23(7):946-950.
65. Stoitzner P., Sparber F., Tripp C.H. Langerhans cells as targets for immunotherapy against skin cancer. Immunol Cell Biol 2010, 88(4):431-437.
66. Yagi H., Hashizume H., Horibe T., et al. Induction of therapeutically relevant cytotoxic T lymphocytes in humans by percutaneous peptide immunization. Cancer Res 2006, 66(20):10136-10144.
67. Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet 1911, 178(4594):814-817.
68. Hurwitz S.H. Medicine: seasonal hay fever-some problems in treatment. Cal West Med 1930, 33(1):520-521.
69. Phillips E.W. Relief of hay-fever by intradermal injections of pollen extract. J Am Med Assoc 1926, 86(3):182-184.
70. Vallery-Radot P., Hangenau J. Asthme d'origine équine. Essai de désensibilisation par des cutiréactions répétées. Bull Soc Méd Hôp Paris 1921, 45:1251-1260. [in French].
71. New York Academy of Medicine, Graduate F., Amberson J.B. Diseases of the respiratory tract: Eighth Annual Graduate Fortnight of the New York Academy of Medicine 1936, W.B. Saunders, Philadelphia, London.
72. Pautrizel R., Cabanieu G., Bricaud H., et al. Sem Hop 1957, 33(22):1394-1403. [in French].
73. Blamoutier P., Blamoutier J., Guibert L. Presse Med 1959, 67:2299-2301. [in French].
74. Blamoutier P, Blamoutier J, Guibert L. Traitement co-saisonnier de la pollinose par l'application d'extraits de pollens sur des quadrillages cutanés: Résultats obtenus en 1959 et 1960. Revue francaise d'allergie 1961;1(2):112-20 [in French].
75. Eichenberger H., Storck H. Co-seasonal desensitization of pollinosis with the scarification-method of Blamoutier. Acta Allergol 1966, 21(3):261-267.
76. Palma-Carlos AG. Traitement co-saisonnier des pollinoses au Portugal par la méthode des quadrillages cutanés. Revue Francaise d'Allergie 1967;7(2):92-5 [in French].
77. Martin-DuPan R.B.F., Neyroud M. Treatment of pollen allergy using the cutaneous checker square method of Blamoutier and Guilbert. Schweiz Rundsch Med Prax 1971, 60(44):1469-1472.
78. Dickel H., Goulioumis A., Gambichler T., et al. Standardized tape stripping: a practical and reproducible protocol to uniformly reduce the stratum corneum. Skin Pharmacol Physiol 2010, 23(5):259-265.
79. Nickoloff B.J., Naidu Y. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J Am Acad Dermatol 1994, 30(4):535-546.
80. Dickel H., Gambichler T., Kamphowe J., et al. Standardized tape stripping prior to patch testing induces upregulation of Hsp90, Hsp70, IL-33, TNF-alpha and IL-8/CXCL8 mRNA: new insights into the involvement of 'alarmins'. Contact Dermatitis 2010, 63(4):215-222.
81. Agostinis F., Forti S., Di Berardino F. Grass transcutaneous immunotherapy in children with seasonal rhinoconjunctivitis. Allergy 2010, 65(3):410-411.
82. Turjanmaa K., Darsow U., Niggemann B., et al. EAACI/GA2LEN position paper: present status of the atopy patch test. Allergy 2006, 61(12):1377-1384.
83. Mondoulet L., Dioszeghy V., Vanoirbeek J.A., et al. Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int Arch Allergy Immunol 2010, 154(4):299-309.
84. Soury D., Barratt G., Ah-Leung S., et al. Skin localization of cow's milk proteins delivered by a new ready-to-use atopy patch test. Pharm Res 2005, 22(9):1530-1536.
85. Werfel T. Epicutaneous allergen administration: a novel approach for allergen-specific immunotherapy?. J Allergy Clin Immunol 2009, 124(5):1003-1004.
86. Harris M.C. HAY FEVER-a comparative clinical evaluation of treatment with aqueous pollen extracts, alum-precipitated pyridine pollen extracts and aqueous pollen in oil emulsions. Calif Med 1962, 97(5):286-290.
87. Scharton-Kersten T., Yu J., Vassell R., et al. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun 2000, 68(9):5306-5313.
88. Glenn G.M., Rao M., Matyas G.R., et al. Skin immunization made possible by cholera toxin. Nature 1998, 391(6670):851.
89. Rechtsteiner G., Warger T., Osterloh P., et al. Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 2005, 174(5):2476-2480.
90. Beignon A.S., Briand J.P., Muller S., et al. Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells. Immunology 2002, 105(2):204-212.
91. Hankin C.S., Cox L., Lang D., et al. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol 2010, 104(1):79-85.
92. Jacobsen L., Niggemann B., Dreborg S., et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007, 62(8):943-948.
93. Braman S.S. The global burden of asthma. Chest 2006, 130(Suppl 1):4S-12S.